A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
about
P1343
Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes.NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B moleculesAntigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapyDirect transport of newly synthesized HLA-DR from the trans-Golgi network to major histocompatibility complex class II containing compartments (MIICS) demonstrated using a novel tyrosine-sulfated chimeraSpecificity of HLA class I antigen recognition by human NK clones: evidence for clonal heterogeneity, protection by self and non-self alleles, and influence of the target cell type.HLA-B27 expression does not modulate intracellular Chlamydia trachomatis infection of cell linesAnti-DNA autoantibody-producing hybridomas of normal human lymphoid cell origin.Immortalisation of human antibody producing cells.Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens.Characterization of the Canine MHC Class I DLA-88*50101 Peptide Binding Motif as a Prerequisite for Canine T Cell Immunotherapy.Dynamics of major histocompatibility complex class I association with the human peptide-loading complex.A tumor-associated antigen specific for human kappa myeloma cells.Antibody producing human-human hybridomas. II. Derivation and characterization of an antibody specific for human leukemia cells.Use of monoclonal antibodies for the characterization of novel DNA-binding proteins recognized by human autoimmune sera.Species-specific differences in chaperone interaction of human and mouse major histocompatibility complex class I molecules.Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins.Role for major histocompatibility complex class I in regulating natural killer cell-mediated killing of virus-infected cellsEfficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.Construction and testing of mouse--human heteromyelomas for human monoclonal antibody production.Generation of human monoclonal antibodies reactive with cellular antigens.UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas.A comprehensive analysis of constitutive naturally processed and presented HLA-C*04:01 (Cw4)-specific peptides.Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.Major histocompatibility complex class I-restricted alloreactive CD4+ T cells.Identification of a dominant self-ligand bound to three HLA B44 alleles and the preliminary crystallographic analysis of recombinant forms of each complex.Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid.Expression and regulation of immunoglobulin heavy chain gene transfected into lymphoid cells.Human hybridomas from patients with malignant disease.HLA-A2 subtypes are functionally distinct in peptide binding and presentation.Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.Human monoclonal antibody recognizing liver-type aldolase B.Autoantibodies against Forssman glycolipids in Graves' disease and Hashimoto's thyroiditis.Establishment of a human monoclonal antibody to Hanganutziu-Deicher antigen as a tumor-associated carbohydrate antigen.Definition of peptide binding motifs amongst the HLA-A*30 allelic group
P2860
Q24339577-EC546D62-62A7-4376-B700-7B57A311BCDEQ24679688-2621323C-7360-4554-BFAF-D8EE71E918BFQ26824676-E329F2AC-5491-4F4F-9AE8-EB1A4D846FC9Q28611873-070B68EE-D155-4C44-A6C6-EBDE74FD7678Q30442878-AE4EBB15-EA59-4C39-A142-3195D96FBFFBQ33552137-3C6C4550-EFF2-455A-84BB-739CEB73FD1BQ34613899-C098B450-09C4-45D1-A74C-7A361EE723D0Q35237160-26B3364E-082E-4028-9C96-70BCC5D98477Q35602952-5CF2A3E3-4045-4393-82F6-456122CFC2BCQ36205561-1DA14B80-23F0-42AB-928C-EF83470D1B17Q36225733-B4E83DE5-8ACF-4ACC-97A2-977724DB9968Q36348213-A0F9E99F-52AD-4ECF-A8DF-8D3DDC2EB412Q36348484-CC732F8A-5CB4-4347-861B-2CA12C470CBEQ36349787-AE31038C-B4BE-4899-9FB2-5533B3723F20Q36364251-F01C337B-8EAE-4068-97E5-39D92BD426ADQ36781303-DC9099AF-D46A-4B9A-9BF9-C1837048016CQ37189816-81DEBAC3-3F68-4051-9481-8909BFF61D82Q37343139-15237D67-F574-42BA-9005-99F7111F493AQ37509769-172EEDFF-D369-4021-B784-F37DE7EA7318Q37608089-15DD54C0-86B0-40BC-B18B-AE9D754EEB01Q37618105-4ED885FC-4FBD-4F66-9E05-DBFCFF57EB7FQ39036828-ABAABF52-5C71-4882-BA69-FA5CB16E7D87Q40511607-9293C6D4-50B2-42E9-B644-07CA767C8435Q40564855-1C595358-53F1-4B2F-865C-DBE37BED6E63Q40705253-ADCF320B-8AF7-497F-82D0-34477C932D3EQ40912686-CF2B96C5-A15D-4140-8332-E04AC48D56B3Q40965471-5DBAE68E-875A-4B79-A5D1-ED814869F27AQ41459613-E1D53BB1-2129-4ED1-9F87-EBC7C81CAB6FQ41505165-EEE72DA5-E3CF-4469-BA43-C6815FFAB2C1Q41815036-3E0F2CF5-4AB1-4839-8241-FF59AF1CFAD9Q42799579-57D8D143-39AB-4119-A247-8A3D50E2F09DQ42855136-07746BC8-2074-4853-A551-BB116A6D758EQ44929069-133E97B8-D5A4-4BDD-9BB3-D03FDA974C09Q45063701-38ECD926-2738-4C6E-A75C-C508EEA1AD94Q56914892-7F418289-5A91-4C00-A209-0C13EB23970E
P2860
A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line.
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
A human-hybridoma system based ...... ma cell leukemia-derived line.
@en
A human-hybridoma system based ...... ma cell leukemia-derived line.
@nl
type
label
A human-hybridoma system based ...... ma cell leukemia-derived line.
@en
A human-hybridoma system based ...... ma cell leukemia-derived line.
@nl
prefLabel
A human-hybridoma system based ...... ma cell leukemia-derived line.
@en
A human-hybridoma system based ...... ma cell leukemia-derived line.
@nl
P2093
P356
P1476
A human-hybridoma system based ...... ma cell leukemia-derived line.
@en
P2093
P304
P356
10.1002/EJI.1830120804
P407
P4510
P577
1982-08-01T00:00:00Z